Welcome to our dedicated page for Inhibrx Biosciences SEC filings (Ticker: INBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Drug-development disclosures are notoriously technical, and Inhibrx Biosciences’ SEC documents can exceed 300 pages of protein-engineering jargon and clinical-trial statistics. If you have ever asked, “How do I navigate Inhibrx Biosciences SEC filings explained simply?” this page is designed for you. Stock Titan’s AI immediately transforms dense terminology into plain-English highlights, so you can spot critical R&D spend, cash-runway updates and pivotal study results without wading through footnotes.
Every filing arrives here the moment it hits EDGAR, from an Inhibrx Biosciences quarterly earnings report 10-Q filing to an Inhibrx Biosciences 8-K material events explained. Our platform pairs each document with AI-powered summaries, keyword search and red-flag alerts. You’ll quickly find answers to natural queries like “Where are Inhibrx Biosciences insider trading Form 4 transactions?” or “What changed in the latest proxy statement executive compensation?” Key forms covered include:
- 10-K & 10-Q – pipeline progress, cash burn and partnership milestones, with Inhibrx Biosciences annual report 10-K simplified for faster reading.
- Form 4 – Inhibrx Biosciences Form 4 insider transactions real-time, flagging executive stock transactions before catalysts.
- DEF 14A – Inhibrx Biosciences proxy statement executive compensation, tied to clinical endpoints.
- 8-K – trial data and financing announcements summarized within minutes.
Use these insights to compare quarter-over-quarter R&D allocations, track upcoming milestone payments, and monitor Inhibrx Biosciences earnings report filing analysis. Whether you’re a biotech analyst, fund manager, or a retail investor understanding Inhibrx Biosciences SEC documents with AI, Stock Titan delivers the full picture—no scientific dictionary required.
Viking Global and affiliated entities reported multiple sales of Inhibrx Biosciences, Inc. (INBX) common stock executed on
Inhibrx Biosciences, Inc. furnished a press release announcing its financial results for the three and six months ended June 30, 2025. The press release is furnished as Exhibit 99.1 to this Current Report and an interactive XBRL cover page is included as Exhibit 104.
The company states the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, so it is subject to different legal treatment than filed disclosures. The report confirms Inhibrx's Nasdaq listing under the ticker INBX and indicates the registrant is an emerging growth company.
Inhibrx Biosciences reported a materially different quarter versus the prior-year period driven by the post‑spin financial position and new financing. Revenue was $1.3 million for the quarter from a Scithera license, while operating expenses were $28.7 million leading to an operating loss of $27.4 million and a net loss of $28.654 million for the three months ended June 30, 2025. The prior-year period included a $2.02 billion gain related to the Merger with the Former Parent, which produced the large net income figure in 2024.
The balance sheet shows $186.6 million cash and equivalents and total assets of $212.1 million, with accumulated deficit of $178.1 million. The company established long-term debt under a 2025 Loan Agreement with Oxford resulting in long-term debt, net of discount, of $99.3 million. Management states existing cash is sufficient to fund operations for at least 12 months. Clinically, the company continues development of ozekibart (INBRX-109) and INBRX-106, and completed full enrollment in its registration‑enabling chondrosarcoma trial in July 2025.
FAQ
What is the current stock price of Inhibrx Biosciences (INBX)?
What is the market cap of Inhibrx Biosciences (INBX)?
